Travere (TVTX) CEO Eric Dube Exercises Options, Sells 400K Shares

What Happened

• Eric M. Dube, Chief Executive Officer of Travere Therapeutics (TVTX), exercised 400,000 vested stock options at $23.34 per share (total exercise cost $9,336,000) between Sept 15–17, 2026, and sold the same 400,000 shares in open‑market transactions over those dates for aggregate gross proceeds of about $25.39 million.
• In effect, this was a cashless exercise (exercise then immediate sale), so these are sales rather than a net purchase or increase in ownership.

Key Details

• Dates and actions: Sept 15–17, 2026 — exercised 400,000 shares (code M) at $23.34; sold 400,000 shares (code S) across multiple trades.
• Sale proceeds by group (weighted averages / ranges per filing): roughly $61.99–$64.95 per share (overall proceeds ≈ $25,390,729). Exercise proceeds paid ≈ $9,336,000.
• Net effect: no change in beneficial ownership from these transactions (400,000 acquired via exercise and 400,000 sold).
• Notable footnotes: at least some sales were made pursuant to a written 10b5‑1 trading plan adopted June 16, 2026; the option was fully vested. Detailed price ranges and weighted averages are reported in the filing.
• Filing status: Form 4 filed Sept 17, 2026 — timely relative to the reported transaction dates.

Context

• For retail investors: this is a routine executive cashless exercise + sale to realize option value and cover exercise/tax costs — it does not necessarily indicate management sentiment about the company. Purchases are generally more informative as bullish signals.
• Technical note: “M” entries reflect option exercises/conversions; “S” entries are open‑market sales.